← Leaderboards
Nirupama Putcha
Johns Hopkins University
$7,704,235
Attributed
$10,620,963
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.5M · FY2015–25$5M$3.8M$2.5M$1.3M$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,620,963 · 4
By mechanism
U01$5,833,457 · 1
R01$3,161,039 · 1
K23$1,044,037 · 1
P30$582,430 · 1
Top collaborators
- Nadia N Hansel3 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Nadia N Hansel$30,283,781
- Meredith C McCormack$14,784,022
- Gregory B Diette$8,022,684
- Irina Petrache$14,015,590
- Laura Marie Paulin$1,678,443
Others in their field
Top investigators on “Exposure To”
- Chanza Baytop · Westat, Inc.$271,217,917
- Dennis R. Burton · Scripps Research Institute$265,781,207
- Myron S Cohen · Family Health International$253,611,624
- Wafaa M. El-Sadr · Columbia University Health Sciences$253,611,624
- George R Seage · Abt Associates, Inc.$221,990,872
- Charles Mattias Mountain · Association Of Universities For Research In Astronomy, Inc.$151,998,810
Research focus
Exposure ToFutureMorbidity - Disease RateCause Of DeathClinical ResearchIndoor AllergenEnvironmental HealthHigh RiskAllergensAllergicResearch PersonnelAsthmaImproved OutcomeLungEpidemiologyCohortEnvironmentHome EnvironmentRisk FactorsImmunologyInfrastructureCohort StudiesEnvironmental InterventionCharacteristics
Grant awards (17)
Clinical trial of omalizumab for allergen sensitized and exposed individuals with COPD$2,771,146
U01 · FY2025 · AI · contact PI
Clinical trial of omalizumab for allergen sensitized and exposed individuals with COPD$541,808
U01 · FY2025 · AI · contact PI
Integrated Health Sciences Facility Core$198,675
P30 · FY2025 · ES · contact PI
Clinical trial of omalizumab for allergen sensitized and exposed individuals with COPD$2,520,503
U01 · FY2024 · AI · contact PI
The Home Environment and Re-hospitalization in COPD study (HEAR COPD)$605,749
R01 · FY2023 · ES · contact PI
Integrated Health Sciences Facility Core$383,755
P30 · FY2023 · ES · contact PI
The Home Environment and Re-hospitalization in COPD study (HEAR COPD)$609,509
R01 · FY2022 · ES · contact PI
The Home Environment and Re-hospitalization in COPD study (HEAR COPD)$627,129
R01 · FY2021 · ES · contact PI
The Home Environment and Re-hospitalization in COPD study (HEAR COPD)$10,096
R01 · FY2021 · ES · contact PI
The Home Environment and Re-hospitalization in COPD study (HEAR COPD)$638,909
R01 · FY2020 · ES · contact PI
The Home Environment and Re-hospitalization in COPD study (HEAR COPD)$669,647
R01 · FY2019 · ES · contact PI
The association of allergic disease with clinical outcomes in COPD.$198,718
K23 · FY2019 · HL · contact PI
The association of allergic disease with clinical outcomes in COPD.$198,718
K23 · FY2018 · HL · contact PI
The association of allergic disease with clinical outcomes in COPD.$198,718
K23 · FY2017 · HL · contact PI
The association of allergic disease with clinical outcomes in COPD.$86,222
K23 · FY2017 · HL · contact PI
The association of allergic disease with clinical outcomes in COPD.$198,718
K23 · FY2016 · HL · contact PI
The association of allergic disease with clinical outcomes in COPD.$162,943
K23 · FY2015 · HL · contact PI